Skip to main content

Almirall Value Stock - Dividend - Research Selection

Almirall

ISIN: ES0157097017, WKN: A0MU8Y

Market price date: 21.01.2022
Market price: 10,92 EUR


Almirall Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 03-08-2021
Cash flow
Net operating cash flow 164.764.000
Capital Expenditures -11.891.000
Free cash flow 152.872.992
Balance sheet
Total Equity 1.302.970.000
Liabilities & Shareholders equity 2.291.110.000
Income statement
Net income 74.280.000
Eps (diluted) 0,390
Diluted shares outstanding 177.980.000
Net sales/revenue 807.427.000

Fundamental ratios calculated on: 21-01-2022

Ratios
Key figures 21-01-2022
Cash flow
P/C 11,80
   
P/FC 12,71
Balance sheet
ROI3,24
ROE56,87
Income statement
P/E28,00
Div. Yield2,84%
P/B1,49
P/S2,41


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolALM.MC
Market Capitalization2.357.236.736,00 USD
CountrySpain
IndicesIBEX 35
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.almirall.com


Description of the company

Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for the central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.almirall.com


NEWS